Larimar Therapeutics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $172,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Larimar Therapeutics is raising $172,500,000.00 in new funding. About Larimar Therapeutics: Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania. Larimar Therapeutics’ proprietary protein replacement therapy platform has the potential to provide disease-modifying therapies that are intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that currently have ineffective or no treatments available.
To learn more about Larimar Therapeutics, visit http://larimartx.com/
Contact:
Carole Ben-Maimon, Chief Executive Officer
844-511-9056
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.